PBLA News and Press, Panbela Therapeutics Inc Com From 03/16/23

2023-03-16 16:33:07 ET Panbela Therapeutics press release ( NASDAQ: PBLA ): Q4 GAAP EPS of -$5.68 misses by $2.08 . General and administrative expenses were $1.7 million in the fourth quarter of 2022, compared to $1.3 million in the fourth quarter of 2021. Research...

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ...

MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 16, 2023, at 4:30 P...

MINNEAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced its first patient enrolled in South Korea for its ASPIRE global ...

Gainers: Reata Pharmaceuticals ( RETA ) +175% . OncoSec Medical ( ONCS ) +94% . B&G Foods ( BGS ) +30% . Nerdy ( NRDY ) +29% . SCYNEXIS ( SCYX ) +29% . Blackboxstocks ( BLBX ) +29% . Red Robin Gourmet Burgers ( RRGB ...

Performance Shipping ( PSHG ) -43% . Novavax ( NVAX ) -28% on Q4 earnings release . Tupperware Brands TUP -25% after posting preliminary results . First Horizon ( FHN ) -23% as TD says it won't receive regulatory OK in time for May close . M...

Disruptive therapeutics company Panbela Therapeutics ( NASDAQ: PBLA ) said it has regained compliance Nasdaq's listing standards after closing an ~$15M public offering of shares and warrants. The public offering closed Jan. 30. Panbela had received a letter from Nasdaq confirming ...

MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA ), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, primarily as a res...

Panbela Therapeutics ( NASDAQ: PBLA ) said Thursday it priced public offering of 6,675,000 shares of its common stock and warrants to purchase up to 13,350,000 shares at $2.25 per share and warrant. The warrants will have an exercise price of $2.75 per share and will expire five y...

MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA) , (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced t...